CCP
APLS

Clough Capital Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Clough Capital Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-83,679
Closed -$7.62M – 204
2023
Q2 		$7.62M Buy
83,679
+55,800
+200% +$4.81M 0.77% 46
2023
Q1 		$1.84M Sell
27,879
-730
-3% -$42.1K 0.2% 111
2022
Q4 		$1.48M Sell
28,609
-14,000
-33% -$743K 0.15% 116
2022
Q3 		$2.91M Sell
42,609
-99,800
-70% -$5.91M 0.31% 45
2022
Q2 		$6.44M Hold
142,409
– – 0.8% 37
2022
Q1 		$7.24M Buy
142,409
+10,660
+8% +$471K 0.55% 59
2021
Q4 		$6.23M Sell
131,749
-6,000
-4% -$236K 0.42% 59
2021
Q3 		$4.54M Hold
137,749
– – 0.28% 70
2021
Q2 		$8.71M Sell
137,749
-351,400
-72% -$18.1M 0.47% 72
2021
Q1 		$21M Buy
489,149
+256,700
+110% +$12.1M 0.94% 42
2020
Q4 		$13.3M Sell
232,449
-173,385
-43% -$7.33M 0.95% 44
2020
Q3 		$12.2M Hold
405,834
– – 0.88% 42
2020
Q2 		$13.3M Hold
405,834
– – 1.3% 25
2020
Q1 		$10.9M Sell
405,834
-113,000
-22% -$4.01M 1.08% 30
2019
Q4 		$15.9M Hold
518,834
– – 1.36% 25
2019
Q3 		$12.5M Sell
518,834
-73,300
-12% -$2.02M 1.03% 29
2019
Q2 		$15M Buy
592,134
+2,400
+0.4% +$48.8K 1.47% 21
2019
Q1 		$11.5M Buy
589,734
+27,000
+5% +$425K 1.01% 32
2018
Q4 		$7.42M Sell
562,734
-26,382
-4% -$405K 0.87% 43
2018
Q3 		$10.5M Buy
589,116
+11,500
+2% +$213K 0.99% 30
2018
Q2 		$12.7M Sell
577,616
-44,000
-7% -$1.01M 1.13% 28
2018
Q1 		$13.7M Sell
621,616
-295,500
-32% -$5.81M 1.31% 22
2017
Q4 		$19.7M Buy
+917,116
New +$13.5M 1.64% 20

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Clough Capital Partners's APLS Position: Q3 2023 in Review

Clough Capital Partners sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 83,679 shares — an estimated $7.62M sold.

Clough Capital Partners first reported a position in APLS in Q4 2017 and held it in 23 quarters. The position peaked at $21M in Q1 2021. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • Clough Capital Partners reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Clough Capital Partners sold 83,679 Apellis Pharmaceuticals shares in Q3 2023, an estimated $7.62M.
  • Clough Capital Partners first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 23 quarters.
  • Clough Capital Partners's Apellis Pharmaceuticals position peaked at $21M in Q1 2021.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Clough Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.